<< Back to News

System Formulary Update
Long-Acting Glycopeptides

Situation

The Long-Acting Glycopeptides class review standardization was approved in November 2022. As a note, restrictions for dalbavancin are still being discussed. Current local restrictions will remain in place until System restrictions are approved.

Background

The following products were reviewed: dalbavancin injection, oritavancin injection, and telavancin injection.

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Dalbavancin 500 mg injection

As a result, the following products will be removed from the inpatient drug formulary:

• Oritavancin 400 mg injection

Note: Stock of this formulary product may vary at individual entities

Formulary/Epic changes will Go-Live on Tuesday, December 27, 2022.